Loading
BC Platforms
BC Platforms is a Zurich-based leader in genomic data management and real-world data analytics, founded in 1997. The company focuses on accelerating medical innovation through its AI-enabled federated architecture and secure data platforms, which support precision medicine and the entire drug lifecycle. With R&D operations in Espoo, Finland, and Singapore, and additional locations in London and Boston, BC Platforms operates a Global Data Partner Network that provides secure access to anonymized clinical and genomic data from over 175 million patients across more than 35 countries. The company offers a range of solutions, including a federated network for connecting biobanks and healthcare institutions, a high-performance data platform for genomic discovery, and an AI-powered Trusted Research Environment (TRE) for secure data analysis. BC Platforms primarily serves the pharmaceutical industry, healthcare organizations, and research institutions, enabling them to leverage big data for improved patient outcomes and innovative research. Its business model is based on subscription services, licensing fees, and research partnerships.
Funding
Every round, secondary, debt facility or acquisition involving BC Platforms that Lounge tracks, newest first.
No rounds recorded yet.
Paid members see the full deals desk — every AI round and exit, filterable by type, sector and country, with investors and reported ARR, plus CSV exports. Developer membership is $9/mo.
See plans →Log inKey numbers
—
0
—
$17M